市場調查報告書
商品編碼
1522925
腎功能測試市場規模、佔有率和成長分析:按產品、按測試、按最終用戶、按地區 - 行業預測,2024-2031Kidney Function Test Market Size, Share, Growth Analysis, By Product, By Test, By End-user, By Region - Industry Forecast 2024-2031 |
腎功能檢測市值將從 2023 年的 8.9515 億美元增至 2022 年的 8.421 億美元,預測期內(2024-2031 年)複合年成長率為 6.3%,到 2031 年將達到 14.594 億美元。美元。
由於多種因素推動該行業向前發展,腎功能檢測市場可望大幅擴張。關鍵影響因素包括大型市場參與企業的大量投資和加強研發力度,這兩者都在推動腎臟護理領域的創新。一個關鍵因素是腎臟疾病的高盛行率,促使人們採取積極的方法來加強診斷和治療。政府措施在營造有利於創新進步的環境方面也發揮著重要作用。例如,2022 年 3 月,Nova Biomedical 宣布將透過在傳統醫院環境之外的即時檢測 (POCT) 環境中促進早期疾病檢測和腎功能篩檢來徹底改變腎臟護理,我們為此宣布了一種革命性工具。臨床研究已經在社區健康中心、藥房、診斷影像中心、醫生辦公室、診所甚至家庭測試等非醫院環境中檢驗了有效性。這項創新有望擴大腎臟健康評估的範圍,透過先進的診斷功能豐富多樣化的環境,並實現積極的醫療保健措施以改善患者的治療效果。
Kidney Function Test Market was valued at USD 842.1 million in 2022 and is expected to rise from USD 895.15 million in 2023 to reach a value of USD 1459.4 million by 2031, at a CAGR of 6.3% during the forecast period (2024-2031).
The Kidney function test market is positioned for significant expansion driven by multiple factors advancing the field. Key contributors include substantial investments by major market players and increased research and development efforts, both driving innovations in Kidney care. A primary catalyst is the high prevalence of kidney diseases, prompting a proactive approach to enhance diagnostics and treatment. Government initiatives also play a crucial role in fostering a conducive environment for transformative advancements. For instance, Nova Biomedical introduced a groundbreaking tool in March 2022 designed to revolutionise Kidney care by facilitating early disease detection and renal function screening in Point-of-Care Testing (POCT) settings outside traditional hospital settings. Clinical studies have validated its efficacy across non-hospital environments, such as community health centres, pharmacies, imaging centres, physician offices, clinics, and even home-based testing. This innovation promises to expand access to Kidney health assessment, empowering diverse settings with advanced diagnostic capabilities and enabling proactive healthcare measures for better patient outcomes.
Top-down and bottom-up approaches were used to estimate and validate the size of the Kidney Function Test market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Kidney Function Test Market Segmental Analysis
The kidney function tests market is segmented into product, test, end-user, and region. Based on product, the market is segmented into dipsticks, disposables, and reagents. Based on tests, the market is segmented into urine tests (urine protein tests, creatinine clearance tests, microalbumin tests), blood tests (serum creatinine tests, glomerular filtration rate tests, blood urea nitrogen tests), and others. Based on end user, the market is segmented into diagnostic laboratories, hospital, research laboratories & institute and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Drivers of the Kidney Function Test Market
The Kidney function test market is experiencing significant growth opportunities propelled by advancements in technology. One such milestone is the innovative system launched by Bloom Diagnostics in August 2022, which introduces a sophisticated approach to detecting a wide range of medical conditions. Central to their offerings is the Bloom Kidney Test, a cutting-edge addition that transforms the assessment of Kidney health. This test introduces a quantitative measurement of cystatin C levels in the blood, enabling precise evaluation of the Glomerular Filtration Rate (GFR) for determining Kidney functionality. It categorizes results into three clear classifications-normal function, mildly decreased function, or decreased function-providing crucial insights into overall Kidney health status. This advancement marks a significant leap forward in enhancing diagnostic capabilities and patient care in nephrology.
Restraints in the Kidney Function Test Market
The expanding Kidney function tests market encounters substantial barriers due to the expensive nature of these diagnostic procedures, especially affecting emerging and underdeveloped countries. The high costs hinder the widespread adoption of these vital tests, creating disparities in access to essential healthcare diagnostics. This affordability gap further exacerbates inequities, limiting early detection and intervention for kidney-related illnesses in these regions, thereby perpetuating health inequalities. In regions with emerging economies or underdeveloped healthcare infrastructure, the costliness of kidney function tests presents a formidable obstacle. These diagnostic procedures are crucial for detecting and managing kidney-related conditions early, yet their high expense restricts their accessibility to a privileged few. This disparity not only obstructs the widespread adoption of essential healthcare measures but also deepens existing inequalities in medical care. Consequently, many individuals in these areas face delayed diagnoses and treatments for kidney ailments, amplifying the burden of preventable health complications. Thus, addressing the financial barriers to kidney function tests is pivotal for promoting more equitable healthcare outcomes globally.
Market Trends of the Kidney Function Test Market
The rising popularity of home diagnostics, exemplified by the growing use of digital urinalysis, is significantly boosting market expansion. This trend underscores a shift towards more convenient and accessible healthcare options. Healthy.io, an Israeli digital health startup, has adeptly identified this trend and introduced an FDA-approved smartphone urinalysis test designed specifically for individuals needing kidney function tests for proteins. This innovation not only meets the increasing demand for personalized healthcare solutions but also illustrates the transformative impact of technology on empowering individuals to monitor their health conveniently from home. In recent times, there has been a notable surge in the demand for home diagnostic tools, particularly digital urinalysis, which is fueling substantial growth in this market segment. This trend reflects a broader movement towards healthcare solutions that prioritize convenience and accessibility. An example of this shift can be seen in Healthy.io, an Israeli digital health startup, which has responded effectively by developing an FDA-cleared smartphone urinalysis test designed for individuals seeking kidney function assessments for proteins. This innovative approach not only caters to the growing need for personalized health monitoring but also demonstrates how technology can empower individuals to manage their health conveniently at home.